US Pharma MarketingFDA suggests regulatory flexibility for assessing psychedelics
FDA leaders in an NEJM article say they Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing and the IRA: Tracking the government's negotiation power…
FDA regulators said they’re open to “innovative approaches” for studying the effects of psychedelic therapies, including the use of comparators other than placebo.
The comments echo recently finalized regulatory guidance and signal ...
Source: Endpoints News